Locally unlocks prodrugs by radiopharmaceutical in tumor for cancer therapy
Science Bulletin · 2024-09 · 69 (17) · 2745-2755
DOI: 10.1016/j.scib.2024.07.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Bulletin, 2024-09. Verfasst von Changlun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Key Laboratory of B…. Hauptthemen laut MEDLINE: Prodrugs, Radiopharmaceuticals, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Chemotherapy is the first-line treatment for cancer, but its systemic toxicity can be severe. Tumor-selective prodrug activation offers promising opportunities to reduce systemic toxicity. Here, we present a strategy for activating prodrugs using radiopharmaceuticals. This strategy enables the targeted release of chemotherapeutic agents due to the high tumor-targeting capability of radiopharmaceuticals. [18F]FDG (2-[18F]-fluoro-2-deoxy-D-glucose), one of the most widely used radiopharmaceuticals in clinics, can trigger Pt(IV) complex for controlled release of axial ligands in tumors, it might be mediated by hydrated electrons generated by water radiolysis resulting from the decay of radionuclide 18F. Its application offers the controlled release of fluorogenic probes and prodrugs in living cells and tumor-bearing mice. Of note, an OxaliPt(IV) linker is designed to construct an [18F]FDG-activated antibody-drug conjugate (Pt-ADC). Sequential injection of Pt-ADC and [18F]FDG efficiently releases the toxin in the tumor and remarkably suppresses the tumor growth. Radiotherapy is booming as a perturbing tool for prodrug activation, and we find that [18F]FDG is capable of deprotecting various radiotherapy-removable protecting groups (RPGs). Our results suggest that tumor-selective radiopharmaceutical may function as a trigger, for developing innovative prodrug activation strategies with enhanced tumor selectivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education…
- Changping Laboratory, Beijing 102206, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, C., Xu, M., Zhang, Z., Zeng, S., Shen, S., Ding, Z., Chen, J., Cui, X. Y., & Liu, Z. (2024). Locally unlocks prodrugs by radiopharmaceutical in tumor for cancer therapy. Science Bulletin, 69(17), 2745-2755. https://doi.org/10.1016/j.scib.2024.07.010
Vancouver
Wang C, Xu M, Zhang Z, Zeng S, Shen S, Ding Z, et al. Locally unlocks prodrugs by radiopharmaceutical in tumor for cancer therapy. Science Bulletin. 2024;69(17):2745-2755. doi:10.1016/j.scib.2024.07.010
BibTeX
@article{Wang2024,
author = {Wang, Changlun and Xu, Mengxin and Zhang, Zihang and Zeng, Senhai and Shen, Siyong and Ding, Zexuan and Chen, Junyi and Cui, Xi-Yang and Liu, Zhibo},
title = {Locally unlocks prodrugs by radiopharmaceutical in tumor for cancer therapy},
journal = {Science Bulletin},
year = {2024},
volume = {69},
number = {17},
pages = {2745--2755},
doi = {10.1016/j.scib.2024.07.010}
}
EUVIMED